Long Yuan

2.4k total citations
56 papers, 1.7k citations indexed

About

Long Yuan is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Long Yuan has authored 56 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 21 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Long Yuan's work include Cancer Immunotherapy and Biomarkers (9 papers), Melanoma and MAPK Pathways (5 papers) and Immune Cell Function and Interaction (5 papers). Long Yuan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Melanoma and MAPK Pathways (5 papers) and Immune Cell Function and Interaction (5 papers). Long Yuan collaborates with scholars based in China, United States and Norway. Long Yuan's co-authors include Rosalin Mishra, Joan T. Garrett, Samar Alanazi, Hima Patel, Gordon J. Freeman, Kathleen M. Mahoney, Benling Xu, Peng Zhao, Xin Xie and Gang Pei and has published in prestigious journals such as PLoS ONE, Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Long Yuan

51 papers receiving 1.7k citations

Peers

Countries citing papers authored by Long Yuan

Since Specialization

Citations

This map shows the geographic impact of Long Yuan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Long Yuan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Long Yuan more than expected).

Fields of papers citing papers by Long Yuan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Long Yuan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Long Yuan. The network helps show where Long Yuan may publish in the future.

Co-authorship network of co-authors of Long Yuan

This figure shows the co-authorship network connecting the top 25 collaborators of Long Yuan. A scholar is included among the top collaborators of Long Yuan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Long Yuan. Long Yuan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Relationship between impaired cerebral lymphatic function and iron deposition, blood flow in VaD: a clinical MRI study 2025 ·Frontiers in Neuroscience ·(unknown), (unknown), Haoran Zhang, (unknown), Long Yuan, Cong Pang, (unknown), Zhongling Zhang, Jinping Xu, Shangjie Chen	0
2	Integration of Clinical Trial Spatial Multiomics Analysis and Virtual Clinical Trials Enables Immunotherapy Response Prediction and Biomarker Discovery 2024 ·Cancer Research ·(unknown), Atul Deshpande, (unknown), Hanwen Wang, Haoyang Mi, Long Yuan, Won Jin Ho, Elizabeth M. Jaffee, Qingfeng Zhu, Robert A. Anders, Mark Yarchoan, Luciane T. Kagohara, Elana J. Fertig, Aleksander S. Popel	13
3	HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers 2023 ·PLoS ONE ·Samar Alanazi, (unknown), Rosalin Mishra, (unknown), Hima Patel, Long Yuan, Sarah J. Storr, (unknown)	4
4	Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence 2023 ·Genome Medicine ·Shuming Zhang, Long Yuan, Ludmila Danilova, Guanglan Mo, Qingfeng Zhu, Atul Deshpande, (unknown), Jennifer H. Elisseeff, Aleksander S. Popel, Robert A. Anders, Elizabeth M. Jaffee, Mark Yarchoan, Elana J. Fertig, Luciane T. Kagohara	56
5	Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma 2022 ·The Oncologist ·(unknown), Qiang Fu, Lingdi Zhao, Xiaomin Fu, Tiepeng Li, Lu Han, Peng Qin, (unknown), (unknown), Zhimeng Li, (unknown), Long Yuan, (unknown), Zibing Wang	9
6	Electroacupuncture May Inhibit Oxidative Stress of Premature Ovarian Failure Mice by Regulating Intestinal Microbiota 2022 ·Oxidative Medicine and Cellular Longevity ·Zixiang Geng, Xiaoli Nie, (unknown), Bingrong Li, Peng Liu, Long Yuan, (unknown), Te Liu, Bimeng Zhang	22
7	Soluble PD-L1 as an early marker of progressive disease on nivolumab 2022 ·Journal for ImmunoTherapy of Cancer ·Kathleen M. Mahoney, Petra Ross‐Macdonald, Long Yuan, Linan Song, (unknown), Megan Wind‐Rotolo, David F. McDermott, F. Stephen Hodi, Toni K. Choueiri, Gordon J. Freeman	55
8	A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies 2022 ·Monoclonal Antibodies in Immunodiagnosis and Immunotherapy ·(unknown), Long Yuan, (unknown), Gordon J. Freeman	11
9	Human Amniotic Fluid Mesenchymal Stem Cell‐Derived Exosomes Inhibit Apoptosis in Ovarian Granulosa Cell via miR‐369‐3p/YAF2/PDCD5/p53 Pathway 2022 ·Oxidative Medicine and Cellular Longevity ·Zixiang Geng, Haiyang Chen, Gang Zou, Long Yuan, Peng Liu, Bingrong Li, (unknown), Fangyuan Jing, Xiaoli Nie, Te Liu, Bimeng Zhang	43
10	Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy 2021 ·Technology in Cancer Research & Treatment ·(unknown), Long Yuan, Hongyan Ni, Benling Xu, Peng Zhao	34
11	VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy 2021 ·Trends in Immunology ·Long Yuan, (unknown), Kathleen M. Mahoney, Gordon J. Freeman	152
12	S-15 in combination of Akt inhibitor promotes the expansion of CD45RA−CCR7+ tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1+Tim-3+ cells as well as regulatory T cells 2019 ·Cancer Cell International ·Benling Xu, Long Yuan, Guangyu Chen, Tiepeng Li, Jinxue Zhou, Chengjuan Zhang, Peng Qin, Musleh M. Muthana, Shengdian Wang, Xuexiang Du, Quanli Gao	6
13	Role of Reactive Oxygen Species and Targeted Therapy in Metastatic Melanoma 2018 ·Rosalin Mishra, Hima Patel, Long Yuan, Joan T. Garrett	3
14	CDKN2A inhibits formation of homotypic cell-in-cell structures 2018 ·Oncogenesis ·Jianqing Liang, Jie Fan, Manna Wang, Zubiao Niu, Zhengrong Zhang, Long Yuan, Yanhong Tai, Zhaolie Chen, Santai Song, Xiaoning Wang, Xiaoqing Liu, Hongyan Huang, Qiang Sun	37
15	Utilization of Reactive Oxygen Species Targeted Therapy to Prolong the Efficacy of BRAF Inhibitors in Melanoma 2018 ·Journal of Cancer ·Long Yuan, Rosalin Mishra, Hima Patel, (unknown), Kenneth D. Greis, Ana Luisa Kadekaro, Edward J. Merino, Joan T. Garrett	23
16	Clinical significance of the programmed death-1+ T cell immunoglobulin domain and mucin domain-3+ frequency on CD4+ T lymphocytes in patients with colorectal cancer 2017 ·Zhonghua shiyan waike zazhi ·Long Yuan, Tao Huang, Benling Xu, Zhenlei Wang, (unknown), Peng Zhao, Guanglong Chen, Quanli Gao	0
17	Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer 2016 ·Oncology Letters ·Peng Yuan, Benling Xu, Chengzheng Wang, Chengjuan Zhang, Miaomiao Sun, Long Yuan	19
18	Resveratrol induces cell cycle arrest via a p53-independent pathway in A549 cells 2014 ·Molecular Medicine Reports ·Long Yuan, Yongrong Zhang, Juan Xia, Bin Liu, Qingyu Zhang, Jie Liu, Liming Luo, Peng Zhou, Zeqing Song, Runzhi Zhu	73
19	Rapamycin and other longevity‐promoting compounds enhance the generation of mouse induced pluripotent stem cells 2011 ·Aging Cell ·Taotao Chen, Shen Li, Jie Yu, (unknown), Ao Guo, Jiekai Chen, Long Yuan, Jian Zhao, Gang Pei	165
20	Effects of compound Red-rooted Salvia and aspirin on platelet aggregation and PKB activity in the elderly patients with ACS 2009 ·Zhongguo xin yao zazhi ·Long Yuan	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact